Oman Medical Journal, 2015 Objective: The aim of this study was to evaluate the role of secondary cytoreductive surgery in Asian patients with recurrent ovarian cancer and to assess prognostic variables on overall post-recurrence survival time.
Rani Akhil Bhat +5 more
doaj +1 more source
Trends in extent of surgical cytoreduction for patients with ovarian cancer.
PLoS ONE, 2021 PurposeTo identify patient and hospital characteristics associated with extended surgical cytoreduction in the treatment of ovarian cancer.MethodsA retrospective analysis using the National Inpatient Sample (NIS) database identified women hospitalized ...
Deanna H Wong +7 more
doaj +3 more sources
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for patients with peritoneal metastases from endometrial cancer [PDF]
, 2017 Background: More information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: This study analyzed clinical,
Biacchi, Daniele +9 more
core +1 more source
BMC Cancer, 2017 Background This study aimed to evaluate the perioperative outcomes and prognostic impact of the consecutive steps of imaging, frailty assessment, and diagnostic laparoscopy (DLS) in patients with advanced epithelial ovarian cancer (EOC). Methods Patients
Kyung Jin Eoh +6 more
doaj +1 more source
Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]
, 2015 Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim +6 more
core +4 more sources
En-block cytoreduction for advanced ovarian cancer
Gynecologic Oncology Reports, 2023 The standard treatment of advanced ovarian, fallopian tube and peritoneal cancer is cytoreductive surgery followed by platinum-based chemotherapy (du Bois et al., 2005). This type of cancer expands through the peritoneum, which is the thin and continuous
Anastasios Pandraklakis +2 more
doaj +1 more source
Evaluation of the relationship between lactacidemia and postoperative complications after surgery for peritoneal carcinomatosis [PDF]
Korean Journal of Anesthesiology, 2021 Background Cytoreductive surgery was developed as a treatment for peritoneal carcinomatosis. However, this surgery is associated with important complications.
Marta Soriano Hervás +7 more
doaj +1 more source
Nowotwory. Journal of Oncology, 2020 Surgical treatment of patients with peritoneal metastases in combination with Hyperthermic intraperitoneal Chemotherapy (HIPEC) and systemic treatments is applied with increasing frequency and, with correct patient qualification, allows for obtaining 5-year survival at a level of 32–52%.
Tomasz Jastrzębski +20 more
openaire +3 more sources
Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis [PDF]
, 2015 BACKGROUND: Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic approach for these patients ...
Accarpio, Fabio +8 more
core +2 more sources
Prognostic factors influencing infectious complications after cytoreductive surgery and HIPEC. Results from a tertiary referral center [PDF]
, 2019 Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in selected patients. High morbidity restrains its wide application.
Carbonari, Ludovica +8 more
core +1 more source